Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550

CompletedOBSERVATIONAL
Enrollment

162

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

CP-690,550

Subjects had to have received CP-690,550 or other blinded study drug in index study. No intervention in this long-term follow-up trial.

Trial Locations (72)

1612

Pfizer Investigational Site, Sofia

11527

Pfizer Investigational Site, Athens

14000

Pfizer Investigational Site, Mexico City

16132

Pfizer Investigational Site, Genova

19002

Pfizer Investigational Site, Guadalajara

19610

Pfizer Investigational Site, Wyomissing

21018

Pfizer Investigational Site, Vinnitsa

28601

Pfizer Investigational Site, Hickory

28602

Pfizer Investigational Site, Hickory

32804

Pfizer Investigational Site, Orlando

33613

Pfizer Investigational Site, Tampa

33614

Pfizer Investigational Site, Tampa

34233

Pfizer Investigational Site, Sarasota

34292

Pfizer Investigational Site, Venice

34474

Pfizer Investigational Site, Ocala

50139

Pfizer Investigational Site, Florence

61107

Pfizer Investigational Site, Rockford

68516

Pfizer Investigational Site, Lincoln

75150

Pfizer Investigational Site, Mesquite

81109

Pfizer Investigational Site, Bratislava

85234

Pfizer Investigational Site, Gilbert

85704

Pfizer Investigational Site, Tucson

91786

Pfizer Investigational Site, Upland

92108

Pfizer Investigational Site, San Diego

94304

Pfizer Investigational Site, Palo Alto

94305

Pfizer Investigational Site, Stanford

98405

Pfizer Investigational Site, Tacoma

7500710

Pfizer Investigational Site, Providencia

7500922

Pfizer Investigational Site, Santiago

7501126

Pfizer Investigational Site, Santiago

12206-1043

Pfizer Investigational Site, Albany

98405-2308

Pfizer Investigational Site, Tacoma

C1034ACO

Pfizer Investigational Site, Buenos Aires

C1114AAH

Pfizer Investigational Site, Buenos Aires

74110-120

Pfizer Investigational Site, Goiânia

22271-100

Pfizer Investigational Site, Rio de Janeiro

01323-903

Pfizer Investigational Site, São Paulo

04266-010

Pfizer Investigational Site, São Paulo

V8V 3P9

Pfizer Investigational Site, Victoria

656 91

Pfizer Investigational Site, Brno

370 01

Pfizer Investigational Site, České Budějovice

128 50

Pfizer Investigational Site, Prague

140 00

Pfizer Investigational Site, Prague

148 00

Pfizer Investigational Site, Praha 11 - Chodov

00000

Pfizer Investigational Site, Santo Domingo

05800

Pfizer Investigational Site, Hyvinkää

54 636

Pfizer Investigational Site, Thessaloniki

H-1036

Pfizer Investigational Site, Budapest

H-5000

Pfizer Investigational Site, Szolnok

H-8200

Pfizer Investigational Site, Veszprém

380 015

Pfizer Investigational Site, Ahmedabad

575 001

Pfizer Investigational Site, Mangalore

411 001

Pfizer Investigational Site, Pune

Unknown

Pfizer Investigational Site, Kitakyushu

Pfizer Investigational Site, Higashihiroshima

Pfizer Investigational Site, Sagamihara

Pfizer Investigational Site, Shinjyuku-ku

06726

Pfizer Investigational Site, México

15-950

Pfizer Investigational Site, Bialystok

60-773

Pfizer Investigational Site, Poznan

81-759

Pfizer Investigational Site, Sopot

02-256

Pfizer Investigational Site, Warsaw

50-088

Pfizer Investigational Site, Wroclaw

00918

Pfizer Investigational Site, San Juan

921 01

Pfizer Investigational Site, Piešťany

012 07

Pfizer Investigational Site, Žilina

302-799

Pfizer Investigational Site, Daejeon

501-757

Pfizer Investigational Site, Gwangju

400-711

Pfizer Investigational Site, Incheon

110-744

Pfizer Investigational Site, Seoul

120-752

Pfizer Investigational Site, Seoul

133-792

Pfizer Investigational Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00414661 - Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550 | Biotech Hunter | Biotech Hunter